Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs ...

The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available, the U.S. health regulator's website ...

Europe's most valuable company has invested billions in Kalundborg on Denmark's coast - but it has many problems.

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

Less than a month after the FDA removed Eli Lilly’s tirzepatide from its shortage list, the agency has done the same for Novo Nordisk’s rival GLP-1 semaglutide, potentially signaling the end of a d | ...

Novo Nordisk’s Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, new data show.

All doses of the two drugs are now listed as available in the U.S., per an FDA database, although the company cautioned ...

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

All doses of Novo Nordisk's weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the FDA's drug shortage database. It is a sign that Novo ...